{"id":"https://openalex.org/W7225319796","doi":"https://doi.org/10.3389/fphar.2026.2002339","title":"Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes","display_name":"Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes","publication_year":2026,"publication_date":"2026-11-05","ids":{"openalex":"https://openalex.org/W7225319796","doi":"https://doi.org/10.3389/fphar.2026.2002339"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.2002339","doi":"https://doi.org/10.3389/fphar.2026.2002339","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2002339","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2002339/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2002339/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101791469","display_name":"Jing Dong","orcid":"https://orcid.org/0000-0002-9353-2246","observed_orcids":["https://orcid.org/0000-0002-9353-2246","https://orcid.org/0009-0002-4519-3275"]},"institutions":[{"id":"https://openalex.org/I4210167027","display_name":"Tangshan Gongren Hospital","ror":"https://ror.org/00sr40296","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210167027"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jing Dong","raw_affiliation_strings":["Department of Oncology, Tangshan Gongren Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Tangshan Gongren Hospital","institution_ids":["https://openalex.org/I4210167027"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100928706","display_name":"Ye Jin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137506752","display_name":"North China University of Science and Technology","ror":"https://ror.org/04z4wmb81","country_code":"CN","type":"education","lineage":["https://openalex.org/I137506752"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ye Jin","raw_affiliation_strings":["College of Clinical Medicine, North China University of Science and Technology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Clinical Medicine, North China University of Science and Technology","institution_ids":["https://openalex.org/I137506752"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5135647580","display_name":"Yaning Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111381250","display_name":"Hebei Medical University","ror":"https://ror.org/04eymdx19","country_code":"CN","type":"education","lineage":["https://openalex.org/I111381250"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yaning Li","raw_affiliation_strings":["Graduate School, Hebei Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School, Hebei Medical University","institution_ids":["https://openalex.org/I111381250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100410690","display_name":"Zhi Zhang","orcid":"https://orcid.org/0000-0002-4205-3181","observed_orcids":["https://orcid.org/0000-0002-4205-3181"]},"institutions":[{"id":"https://openalex.org/I4210167027","display_name":"Tangshan Gongren Hospital","ror":"https://ror.org/00sr40296","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210167027"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhi Zhang","raw_affiliation_strings":["Department of Oncology, Tangshan Gongren Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Tangshan Gongren Hospital","institution_ids":["https://openalex.org/I4210167027"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5158498924","display_name":"Xuemei Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137506752","display_name":"North China University of Science and Technology","ror":"https://ror.org/04z4wmb81","country_code":"CN","type":"education","lineage":["https://openalex.org/I137506752"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xuemei Zhang","raw_affiliation_strings":["College of Life Science, North China University of Science and Technology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Life Science, North China University of Science and Technology","institution_ids":["https://openalex.org/I137506752"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5158498924"],"corresponding_institution_ids":["https://openalex.org/I137506752"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.6029999852180481,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.6029999852180481,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.3375999927520752,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10619","display_name":"Esophageal Cancer Research and Treatment","score":0.04479999840259552,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/esophageal-cancer","display_name":"esophageal cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9850000143051147},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9649999737739563},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/chemoimmunotherapy","display_name":"chemoimmunotherapy","score":0.7760000228881836},{"id":"https://openalex.org/keywords/esophagitis","display_name":"esophagitis","score":0.9129999876022339},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8230000138282776},{"id":"https://openalex.org/keywords/immune-related-endocrinopathy","display_name":"immune-related endocrinopathy","score":0.7179999947547913},{"id":"https://openalex.org/keywords/time-to-onset-of-adverse-events","display_name":"time to onset of adverse events","score":0.800000011920929},{"id":"https://openalex.org/keywords/mortality","display_name":"mortality","score":0.5879999995231628},{"id":"https://openalex.org/keywords/real-world-safety-data","display_name":"real-world safety data","score":0.6140000224113464},{"id":"https://openalex.org/keywords/fda-adverse-event-reporting-system","display_name":"FDA Adverse Event Reporting System","score":0.7710000276565552},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.7979999780654907},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.4440000057220459}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9473999738693237},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.7333999872207642},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6985999941825867},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6819000244140625},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.6256999969482422},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6194000244140625},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5806000232696533},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5217999815940857},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.413100004196167},{"id":"https://openalex.org/C2779742542","wikidata":"https://www.wikidata.org/wiki/Q372701","display_name":"Esophageal cancer","level":3,"score":0.3693000078201294},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.36390000581741333},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32910001277923584},{"id":"https://openalex.org/C2781005205","wikidata":"https://www.wikidata.org/wiki/Q5398631","display_name":"Esophageal candidiasis","level":4,"score":0.32910001277923584},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.3050999939441681},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.29739999771118164},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.296999990940094},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.2930000126361847},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.2865999937057495},{"id":"https://openalex.org/C2778220009","wikidata":"https://www.wikidata.org/wiki/Q160105","display_name":"Cervical cancer","level":3,"score":0.2833999991416931},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.26100000739097595},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.2526000142097473}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fphar.2026.2002339","doi":"https://doi.org/10.3389/fphar.2026.2002339","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2002339","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2002339/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:2430abbb17204981b4b8b313d88eb2e8","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/2430abbb17204981b4b8b313d88eb2e8","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.2002339","doi":"https://doi.org/10.3389/fphar.2026.2002339","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2002339","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2002339/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225319796.pdf","grobid_xml":"https://content.openalex.org/works/W7225319796.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W3199359409","https://openalex.org/W3200109370","https://openalex.org/W4206384216","https://openalex.org/W4214915284","https://openalex.org/W4224260137","https://openalex.org/W4281621907","https://openalex.org/W4281669451","https://openalex.org/W4306166217","https://openalex.org/W4318203608","https://openalex.org/W4318979631","https://openalex.org/W4399566827","https://openalex.org/W4399756086","https://openalex.org/W4401728224","https://openalex.org/W4405122992","https://openalex.org/W4406628329","https://openalex.org/W4406873281","https://openalex.org/W4408247348","https://openalex.org/W4408841790","https://openalex.org/W4412785661","https://openalex.org/W4416778034","https://openalex.org/W7124854388","https://openalex.org/W7137823882","https://openalex.org/W7140998150","https://openalex.org/W7147193874","https://openalex.org/W7155083252","https://openalex.org/W7163923294"],"related_works":["https://openalex.org/W4308871954","https://openalex.org/W7116660715","https://openalex.org/W4376224236","https://openalex.org/W4416030814","https://openalex.org/W4289517421","https://openalex.org/W4306166217","https://openalex.org/W4311867141","https://openalex.org/W3038016344","https://openalex.org/W4388676022","https://openalex.org/W4283521393"],"abstract_inverted_index":{"Background":[0],"Immune":[1],"checkpoint":[2],"inhibitors":[3],"(ICIs)":[4],"have":[5],"become":[6],"an":[7],"important":[8],"component":[9],"of":[10,238,328],"systemic":[11],"therapy":[12,46,302],"for":[13,20,69,123,269,273,325],"esophageal":[14,51,70],"cancer,":[15],"but":[16,315],"real-world":[17],"safety":[18],"data":[19],"combining":[21],"ICIs":[22],"with":[23,83,149,224,235,281],"taxane-":[24],"and":[25,40,47,86,102,114,118,147,174,218,262,308,331],"platinum-based":[26],"chemotherapy":[27],"remain":[28],"limited.":[29],"This":[30],"study":[31],"compared":[32],"adverse-event":[33],"(AE)":[34],"profiles,":[35],"time":[36],"to":[37],"onset":[38,312],"(TTO),":[39],"reported":[41,124,283,317],"mortality":[42,266,284,318],"between":[43],"ICI-based":[44,300],"combination":[45,232,270,278,301,335],"ICI":[48],"monotherapy":[49,88,287],"in":[50,231],"cancer.":[52],"Methods":[53],"Using":[54],"the":[55,77,152,323],"FDA":[56],"adverse":[57],"event":[58],"reporting":[59,96,104],"system":[60],"(FAERS),":[61],"we":[62],"screened":[63],"reports":[64,130,223],"from":[65],"Q3/2019":[66],"through":[67],"Q1/2026":[68],"cancer":[71],"involving":[72],"pembrolizumab":[73],"or":[74],"nivolumab":[75],"as":[76],"primary":[78],"suspect.":[79],"Combination":[80],"included":[81,89],"immunotherapy":[82,90],"a":[84,304],"taxane":[85],"platinum;":[87],"alone.":[91],"Disproportionality":[92],"was":[93,110,267,279],"assessed":[94],"via":[95],"odds":[97,285],"ratios":[98,105],"(":[99,106,155,167,177,193,202,211,241,248,252,288],"RORs":[100],")":[101],"proportional":[103],"PRRs":[107],").":[108],"TTO":[109,225],"evaluated":[111],"using":[112],"Kaplan-Meier":[113],"Cox":[115],"models":[116],",":[117,157,160,169,172,179,182,195,198,204,207,213,216,243,250,291,294],"logistic":[119],"regression":[120],"examined":[121],"factors":[122],"mortality.":[125],"Results":[126],"Among":[127,221],"1,580":[128],"eligible":[129],"(103":[131],"combination,":[132,141],"1,477":[133],"monotherapy),":[134],"distinct":[135,305],"AE":[136,306,311],"signal":[137,154],"profiles":[138],"emerged.":[139],"In":[140,184],"prominent":[142],"signals":[143,186],"were":[144,187],"gastrointestinal,":[145,330],"hematologic,":[146,329],"respiratory,":[148],"esophagitis":[150],"showing":[151],"strongest":[153],"ROR":[156,168,178,194,203,212],"61.97;":[158],"95%CI":[159,171,181,197,206,215,293],"22.80\u2013168.48),":[161],"followed":[162],"by":[163],"decreased":[164],"lymphocyte":[165],"count":[166],"59.68;":[170],"28.99\u2013122.83)":[173],"behaviour":[175],"disorder":[176],"42.85;":[180],"13.58\u2013135.17).":[183],"monotherapy,":[185,234,314],"more":[188],"immune-mediated,":[189],"including":[190],"immune-mediated":[191,200,209],"cystitis":[192],"261.05;":[196],"113.92\u2013598.18),":[199],"cholangitis":[201],"87.65;":[205],"41.36\u2013185.78),":[208],"endocrinopathy":[210],"85.51;":[214],"27.19\u2013268.89)":[217],"so":[219],"on.":[220],"571":[222],"data,":[226],"AEs":[227],"occurred":[228],"significantly":[229,309],"earlier":[230,310],"than":[233,286,313],"median":[236],"TTOs":[237],"23":[239],"days":[240,247],"IQR":[242,249],"8-72)":[244],"vs.":[245,271],"49":[246],"21\u2013129)":[251],"log-rank":[253],"P":[254,296],"<":[255],"0.001),":[256],"consistent":[257],"across":[258],"age,":[259],"sex,":[260],"weight,":[261],"reporting-year":[263],"subgroups.":[264],"Reported":[265],"6.8%":[268],"21.1%":[272],"monotherapy.":[274],"After":[275],"multivariable":[276],"adjustment,":[277],"associated":[280],"lower":[282,316],"adjusted":[289],"OR":[290],"0.27;":[292],"0.06\u20130.77;":[295],"=":[297],"0.033).":[298],"Conclusion":[299],"showed":[303],"profile":[307],"odds.":[319],"These":[320],"findings":[321],"underscore":[322],"need":[324],"early":[326],"monitoring":[327],"respiratory":[332],"toxicities":[333],"during":[334],"therapy.":[336]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-11-06T00:00:00"}